Data regarding the relative risk of toxicity with ICIs and EGFR-TKIs in NSCLC patients in several studies have revealed more severe irAEs when EGFR-TKIs were used in combination with ICIs or used after ICIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.